← FDA DRUG APPROVALS

FDA ANDA · ANDA077657

LORAZEPAM

Sponsor: RISING

APPLICATION
ANDA077657
TYPE
ANDA
ORIGINAL APPROVAL
2006-03-16
LATEST ACTION
2026-01-05
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LORAZEPAMDiscontinued
LORAZEPAM 1MG · TABLET · ORAL
LORAZEPAMDiscontinued
LORAZEPAM 2MG · TABLET · ORAL
LORAZEPAMDiscontinued
LORAZEPAM 0.5MG · TABLET · ORAL

Approval history

2026-01-05Labeling · Supplement 12 · standardAP
2025-03-26Labeling · Supplement 9 · standardAP
2025-03-26Labeling · Supplement 7 · standardAP
2025-03-26Labeling · Supplement 11 · standardAP
2010-09-08Labeling · Supplement 4AP
2006-03-16OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →